Introduction
============

Parkinson's disease (PD) is the second most frequent type of neurodegenerative disorder.[@b1-ndt-11-059] The cardinal symptoms of PD are static tremors, rigidity, bradykinesia, and impairment of postural reflexes.[@b2-ndt-11-059] Despite decades of research, the cause of PD is poorly understood. To date, age is the only proven risk factor for PD.[@b3-ndt-11-059],[@b4-ndt-11-059] Several other risk factors such as gene polymorphism, tobacco use, alcohol and caffeine consumption, pesticides, and history of head trauma, hypertension, and diabetes mellitus have been widely investigated, but the impact of most of these factors on the risk of developing PD remains uncertain.[@b4-ndt-11-059],[@b5-ndt-11-059]

PD is more common in men than in women, with a male-to-female ratio of age-adjusted incidence rates of 1.5,[@b6-ndt-11-059] and experimental studies have shown a neuroprotective effect of estrogen on the nigrostriatal dopaminergic system.[@b7-ndt-11-059] Based on the sex difference and experimental evidence, the role of female hormones in the etiology of PD has been the subject of speculation for many years. Epidemiologic studies evaluating the relationship between the risk of PD and hormone replacement therapy (HRT) in women have yielded inconsistent results.[@b8-ndt-11-059]--[@b21-ndt-11-059] This discrepancy in the results may be related to insufficient statistical power of individual studies. Thus, a meta-analysis of published case--control and cohort studies was performed to derive the most precise estimation of association between risk of PD and HRT.

Materials and methods
=====================

Search strategy
---------------

Studies on the association between risk of PD and HRT published before June 2, 2014 were identified from PubMed and EMBASE databases. No language limitation was imposed during our literature search. The search string was as follows: ("hormone" OR "exogenous hormones" OR "exogenous hormones use" OR "hormone replacement therapy" OR "menopausal hormone therapy" OR "estrogen replacement therapy" OR "menopausal hormone use") AND ("Parkinson's disease" OR "shaking palsy" OR "Parkinsonism" OR "paralysis agitans"). Furthermore, reference lists of relevant articles and reviews were also screened for additional studies.

Selection criteria
------------------

The following criteria were adopted to identify eligible studies: 1) a case--control or cohort study evaluating the relationship between PD risk and HRT; 2) reporting the estimates of the relative risk (RR)/odds ratio/hazard ratio with corresponding 95% confidence intervals (CIs) or data sufficient to calculate them; 3) when more than one report was published on the same study population, we considered only the most informative one in our analysis; 4) we excluded review, meta-analysis, conference abstract, and cross-sectional studies.

Data extraction and assessment of methodological quality
--------------------------------------------------------

Data extraction and study quality assessment were independently conducted by two authors. The data extracted from each article included the first author's surname, publication year, area where the study was performed, study design, sample size, method of exposure assessment, type of hormone use, covariates for adjustment, and the adjusted risk estimates with corresponding 95% CIs. Assessment of research quality was performed according to the criteria of the Newcastle-- Ottawa Scale (NOS), which was proposed by Wells for meta-analysis of observational studies.[@b22-ndt-11-059] Detailed grading standards consist of: selection (maximum score =4\*), comparability (maximum score =2\*), and exposure or outcome (maximum score =3\*). In our meta-analysis, a study with more than six points was considered to be of relatively higher quality.

Statistical analysis
--------------------

All statistical analyses were conducted with STATA software (v12.0; College Station, TX, USA). The pooled RRs with corresponding 95% CIs were calculated with a random-effects model (DerSimonian--Laird method).[@b23-ndt-11-059] Statistical heterogeneity was assessed using the *Q* statistic (defining significant heterogeneity as a *P*-value of \<0.10) and *I*^2^ statistic (defining significant heterogeneity as *I*^2^\>50%).[@b24-ndt-11-059],[@b25-ndt-11-059] Subgroup analyses were performed according to study design (cohort vs case--control studies), type of controls for the case--control studies (population-based vs hospital-based controls studies), geographic region (North America vs Europe), study quality (high vs low), type of HRT (estrogen vs progesterone), and adjustment for age (yes vs no). We performed sensitivity analysis by excluding one study at a time to evaluate the robustness of the overall results. Publication bias was evaluated using Egger's linear regression test.[@b26-ndt-11-059]

As the most frequent definition of exposure among the studies was "ever versus never use of hormone replacement therapy", this was chosen to be the focus of the main analysis. Moreover, short-term use of HRT was defined as a duration of \<5 years, and long-term use as a duration of ≥5 years. When more than one exposure in a study category fell into the same level, we pooled the corresponding estimates using Hamling's method.[@b27-ndt-11-059] This method takes into account the correlation between estimates.

Results
=======

Search results and study characteristics
----------------------------------------

[Figure 1](#f1-ndt-11-059){ref-type="fig"} provides the flowchart for the selection of articles. We identified 2,193 publications from the database search. Based on our inclusion criteria, a total of 14 studies published between 1998 and 2014 were included.[@b8-ndt-11-059]--[@b21-ndt-11-059] [Table 1](#t1-ndt-11-059){ref-type="table"} presents the main characteristic of the included studies. There were ten case--control and four cohort studies. Seven studies were performed in the US, four in Italy, two in Denmark, and one in Belgium. Regarding the type of hormone use, seven studies focused on the use of estrogen, five involved total hormone use, and two studies provided data on special types of hormones (ie, estrogen and/or progesterone). Data on hormone use were ascertained by a self-reported questionnaire, telephone interview, face-to-face interview, or reviewing medical records. The type and number of potential confounders varied between studies: age, race, smoking, coffee/caffeine, education, positive familial history, age at menopause, type of menopause, alcohol, oral contraceptive, parity, respondent type, pesticide use, degree of urbanization, family PD history, and age at first symptom.

Synthesis of results for hormone replacement therapy and risk of Parkinson's disease
------------------------------------------------------------------------------------

[Figure 2](#f2-ndt-11-059){ref-type="fig"} shows the forest plots for ever users versus never users of HRT. The pooled RR for case--control, cohort studies, and all studies were 0.79 (95% CI: 0.62--1.02, *P~Q~*=0.189, *I*^2^=27.8%), 1.24 (95% CI: 1.10--1.41, *P~Q~* =0.758, *I*^2^=0.0%), and 1.00 (95% CI: 0.84--1.20, *P~Q~* =0.016, *I*^2^=50.3%), respectively. In further analysis according to type of controls for the case--control studies, no significant association was observed in population-based case--control studies or hospital-based case--control studies ([Table 2](#t2-ndt-11-059){ref-type="table"}).

In the subgroup analysis by geographic region, the pooled risk estimates were 1.12 (95% CI: 0.92--1.36, *P~Q~*=0.074, *I*^2^=47.9%) for North America and 0.86 (95% CI: 0.63--1.16, *P~Q~* =0.162, *I*^2^=34.8%) for European countries.

In the subgroup analysis by study quality, an inverse association was found in the low-quality group (RR: 1.16, 95% CI: 1.02--1.31, *P~Q~* =0.309, *I*^2^=14.6%), whereas a positive association was found in the high-quality group (RR: 0.58, 95% CI: 0.40--0.82, *P~Q~* =0.633, *I*^2^=0.0%).

In the subgroup analysis by adjustment for age, no significant correlation was observed neither in the adjusted group (RR: 1.05, 95% CI: 0.88--1.26, *P~Q~* =0.050, *I*^2^=46.8%) nor in the unadjusted group (RR: 0.87, 95% CI: 0.49--1.53, *P~Q~* =0.057, *I*^2^=60.1%).

In the subgroup analysis by type of female hormone use, the cumulative estimated risks associated with ever use of estrogen replacement therapy (ERT) was 1.05 (95% CI: 0.79--1.40, *P~Q~* =0.021, *I*^2^=54.1%). Among the included studies, only one study assessed the association between progesterone use and PD risk (RR: 3.41, 95% CI: 1.23--9.47).

Four studies provided data on the duration of HRT use and PD risk.[@b13-ndt-11-059],[@b17-ndt-11-059],[@b19-ndt-11-059],[@b21-ndt-11-059] The pooled RRs were 1.22 (95% CI: 1.03--1.44, *P~Q~* =0.954, *I*^2^=0.0%) for short-term use and 1.15 (95% CI: 0.97--1.34, *P~Q~* =0.259, *I*^2^=25.4%) for long-term use.

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analyses were performed to evaluate the effect of one single study on the overall estimate by sequentially excluding each study at one time. The sensitivity analyses suggested that the overall result was robust ([Figure 3](#f3-ndt-11-059){ref-type="fig"}). A publication bias was identified using Egger's linear regression test (*P*=0.013). Then, the trim-and-fill method, which estimates the number of potential missing studies resulting from publication bias, was also implemented.[@b28-ndt-11-059] This method identified any possible missing studies; the adjustment-estimated RR with corresponding 95% CI was not changed, indicating that our result was stable.

Discussion
==========

In this meta-analysis of 14 case--control and cohort studies involving more than 2,900 cases and 511,000 non-case subjects, HRT does not appear to be associated with PD risk. The results from this meta-analysis are similar to those conducted by Noyce et al.[@b5-ndt-11-059] The previous meta-analysis of nine observational studies found a significant inverse association between HRT and PD risk in case--control studies, but a significant positive association in cohort studies. The main advantages of the present meta-analysis are the inclusion of a large number of subjects, addressing the variability between studies (ie, type of controls for the case--control studies, geographic region, study quality, type of HRT, adjustment factor, and method of exposure assessment), and performing dose-response analysis of duration. Therefore, our results provided a more precise and valid assessment of the association between HRT and PD risk.

In the subgroup analysis according to geographic area, no significant association was observed in the North America or Europe studies. When stratified by quality of the included studies, an inverse association was observed in the low-quality group. However, a positive association emerged for the high-quality group. This discrepancy may be related to the study design. In the low-quality group, the included studies were hospital-based case--control studies. The likelihood of recall and selective biases may be greatly increased. Additionally, in further analyses according to adjustment for age, no significant correlation was observed in the adjusted group or in the unadjusted group. Thus, findings from the high-quality group may be distorted by age, a proven risk factor for PD.

The correlation between specific types of HRT (ie, estrogen and/or progesterone) and PD risk was explored in nine studies.[@b8-ndt-11-059]--[@b10-ndt-11-059],[@b13-ndt-11-059]--[@b17-ndt-11-059],[@b20-ndt-11-059] The risk estimates were not significant, except for two, from the Cancer Prevention Study II[@b13-ndt-11-059] and the Kaiser Permanente Medical Care Program (KPMCP) of Northern California.[@b16-ndt-11-059] Ascherio et al found ERT was correlated with a higher risk of death from PD.[@b13-ndt-11-059] In KPMCP, estrogen use was associated with a 2.6-fold increased risk of PD.[@b16-ndt-11-059] In our meta-analysis, we found no evidence of a meaningful correlation between ERT and PD risk. Moreover, use of progesterone replacement therapy was investigated in the Nurses' Health Study with 22 years of follow-up.[@b17-ndt-11-059] Simon et al found the use of progestin alone was associated with a three-fold higher PD risk.[@b17-ndt-11-059]

Evaluation of a dose--risk relationship in a meta-analysis of observational studies provides evidence for a suspected cause and effect relationship between exposure and disease. Among the 14 individual studies, five studies performed a dose-response analysis of duration of HRT use.[@b13-ndt-11-059],[@b16-ndt-11-059],[@b17-ndt-11-059],[@b19-ndt-11-059],[@b21-ndt-11-059] All of these studies showed no indication of trend for duration. However, Popat et al in KPMCP found the direction and strength of the relationship between HRT and PD risk lay on the type of menopause.[@b16-ndt-11-059] PD risk increased with longer duration of estrogen therapy in women with a history of hysterectomy compared with never users. There was an approximately two-fold increased risk of PD associated with ≤10 years of estrogen therapy and three-fold increased risk of PD associated with \>10 years of estrogen therapy (*P*-value for linear trend \<0.05). On the contrary, decreasing risk with increasing duration of HRT emerged in women with natural menopause. The significance of this finding was unclear. Therefore, the joint effects of type of menopause and HRT on PD risk needs further discussion. In addition, we performed a meta-analysis of duration of HRT use in relation to PD risk. We defined short-term use as a duration of \<5 years, and long-term use as a duration of ≥5 years. According to our criteria, only four studies were identified for our dose-risk analysis.[@b13-ndt-11-059],[@b17-ndt-11-059],[@b19-ndt-11-059],[@b21-ndt-11-059] The results demonstrated that short-term use was associated with an increased risk of PD, but the association between long-term use and PD risk was not statistically significant. Concerning limited data involving the dose-effect analysis, we cannot exclude that our finding, of an increased risk of PD in women with short-term use of HRT, is a chance finding.

In recent years, several studies have investigated the role of HRT in the improvement of motor symptoms in postmenopausal women with PD.[@b29-ndt-11-059]--[@b32-ndt-11-059] Blanchet et al found 17β-estradiol has a slight or antiparkinsonian effect without consistently altering dyskinesias in their double-blind, placebo-controlled, two-arm crossover study of high-dose transdermal 17β-estradiol in eight postmenopausal women with mild-to-moderate PD.[@b29-ndt-11-059] In the latter, 8-week double-blind, parallel-group, prospective study with 40 subjects, Tsang et al found a statistically significant improvement of motor function in those women receiving low-dose estrogen (0.625 mg/day), with a mean 3.5-point improvement on the motor Unified Parkinson's Disease Rating Scale (UPDRS) score.[@b30-ndt-11-059] However, a placebo-controlled, randomized, double-blind trial involving 12 postmenopausal female PD patients under the age of 80 years revealed estradiol had no significant dopaminergic effect, whereas progesterone appeared to have an antidopaminergic effect.[@b31-ndt-11-059] A more recent multicenter randomized, double-blind, placebo-controlled pilot trial from the Parkinson Study Group POETRY Investigators showed a nonsignificant trend of symptomatic and functional improvement in those receiving ERT.[@b32-ndt-11-059] Concerning the small number of participants included in each original study, it is conceivable that the conflicting results were due to the small sample size. Moreover, a double-masked, placebo-controlled, parallel-group, single-center trial in 30 male PD patients investigated the effect of testosterone therapy.[@b33-ndt-11-059] Okun et al found that there was no significant improvement of the motor and nonmotor symptoms in the testosterone therapy group compared with the placebo group.[@b33-ndt-11-059] The authors were also aware of the possibility that the observed null effect may have resulted from various limitations, including the small sample size, a strong placebo effect with intramuscular therapy, and the short follow-up period. Therefore, whether sex hormones play a role in the improvement of PD symptoms also remains for future study and more well-designed studies are warranted to clarify this issue.

Our study also had several limitations. First, as a meta-analysis of observational studies, we cannot rule out the probability that the observed null association between HRT and PD risk could be due to unmeasured or residual confounding. Second, some PD cases were identified by self-reports. It is inevitable that some cases were missed or misdiagnosed. Thus, the true association may be underestimated to a degree. Third, misclassification or measurement errors for HRT may have distorted the association, because our analyses were based on the data which were ascertained at baseline, and the changes of exposure were not addressed during the follow-up. Fourth, publication bias was observed in our meta-analysis. However, the results from the trim-and-fill method showed the overall results were robust.

In conclusion, the present meta-analysis provided little support for the hypothesis of a protective effect of HRT on PD risk. However, the significantly increased risk of PD in cohort studies remains to be clarified.
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![Flow diagram of literature search and selection.](ndt-11-059Fig1){#f1-ndt-11-059}

![Forest plots of HRT and PD risk.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** CI, confidence interval; HRT, hormone replacement therapy; PD, Parkinson's disease; RR, relative risk.](ndt-11-059Fig2){#f2-ndt-11-059}

![Sensitivity analyses for HRT and PD risk.\
**Abbreviations:** CI, confidence interval; HRT, hormone replacement therapy; PD, Parkinson's disease.](ndt-11-059Fig3){#f3-ndt-11-059}

###### 

Summary of the characteristics of included studies in this meta-analysis

  Study                                Country   Study design   Sample size   Exposure variables   Exposure assessment   Matching or adjustments[¶](#tfn1-ndt-11-059){ref-type="table-fn"}   Study quality[\#](#tfn2-ndt-11-059){ref-type="table-fn"}
  ------------------------------------ --------- -------------- ------------- -------------------- --------------------- ------------------------------------------------------------------- ----------------------------------------------------------
  Marder et al[@b8-ndt-11-059]         USA       PBCC           87/989        ERT                  NR                    (1), (2)                                                            6[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Benedetti et al[@b9-ndt-11-059]      USA       PBCC           72/72         ERT                  Medical record        (5), (7)                                                            6[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Baldereschi et al[@b10-ndt-11-059]   Italy     PBCC           55/2,136      ERT                  In-person interview   (1), (3), (4), (5), (13)                                            7[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Martignoni et al[@b11-ndt-11-059]    Italy     HBCC           150/300       HRT                  In-person interview   NR                                                                  4[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Pals et al[@b12-ndt-11-059]          Belgium   HBCC           167/135       HRT                  Self-reported         (1), (6)                                                            5[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Ascherio et al[@b13-ndt-11-059]      USA       Cohort         340/238,058   ERT                  Self-reported         (1), (3), (4), (7), (8), (9), (11)                                  7[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Currie et al[@b14-ndt-11-059]        USA       HBCC           68/72         ERT                  In-person interview   \(1\)                                                               5[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Ragonese et al[@b15-ndt-11-059]      Italy     PBCC           131/131       ERT                  Self-reported         (1), (3), (4), (5), (9)                                             6[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Popat et al[@b16-ndt-11-059]         USA       HBCC           178/189       HRT, ERT             In-person interview   (1), (3), (7), (8), (12)                                            7[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Simon et al[@b17-ndt-11-059]         USA       Cohort         244/121,701   HRT, ERT, PRT        Self-reported         (1), (3)                                                            6[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Nicoletti et al[@b18-ndt-11-059]     Italy     HBCC           200/290       HRT                  Self-reported         NR                                                                  4[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Rugbjerg et al[@b20-ndt-11-059]      Denmark   Cohort         77/27,466     ERT                  Self-reported         \(1\)                                                               7[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Liu et al[@b19-ndt-11-059]           USA       Cohort         410/119,166   HRT                  Self-reported         (1), (2), (3), (4), (7), (8), (10)                                  8[\*](#tfn2-ndt-11-059){ref-type="table-fn"}
  Greene et al[@b21-ndt-11-059]        Denmark   PBCC           765/765       HRT                  Telephone interview   (1), (3), (4), (5), (14), (15), (16)                                8[\*](#tfn2-ndt-11-059){ref-type="table-fn"}

**Notes:**

Matching or adjustments were: (1) age, (2) race, (3) smoking, (4) coffee/caffeine, (5) education, (6) positive familial history, (7) age at menopause, (8) type of menopause, (9) alcohol, (10) oral contraceptive, (11) parity, (12) respondent type, (13) pesticide-use, (14) degree of urbanization, (15) family PD history, (16) age at first symptom.

denotes study quality ranging from 0 stars to 9 stars.

**Abbreviations:** ERT, estrogen replacement therapy; HBCC, hospital-based case--control study; HRT, hormone replacement therapy; NR, not reported; PBCC, population-based case--control study; PRT, progesterone replacement therapy.

###### 

Summary of RR estimates between risk of Parkinson's disease and HRT in women

  Group                    Meta-analysis   *P~Q~*              *I*^2^   
  ------------------------ --------------- ------------------- -------- -------
  All studies              14              1.00 (0.84--1.20)   0.016    50.3%
  Study design                                                          
   Case--control studies   10              0.79 (0.62--1.02)   0.189    27.8%
   PBCC                    5               0.89 (0.70--1.13)   0.553    0.0%
   HBCC                    5               0.73 (0.45--1.18)   0.066    54.7%
   Cohort studies          4               1.24 (1.10--1.41)   0.758    0.0%
  Geographic region                                                     
   North America           7               1.12 (0.92--1.36)   0.074    14.6%
   Europe                  7               0.86 (0.63--1.16)   0.162    34.8%
  Study quality                                                         
   High                    10              1.16 (1.02--1.31)   0.309    14.6%
   Low                     4               0.58 (0.40--0.82)   0.633    0.0%
  Adjusted for age                                                      
   Yes                     10              1.05 (0.88--1.26)   0.050    46.8%
   No                      4               0.87 (0.49--1.53)   0.057    60.1%
  Type of HRT                                                           
   ERT                     9               1.05 (0.79--1.40)   0.021    54.1%
   PRT                     1               3.41 (1.23--9.47)   NA       NA

**Abbreviations:** CI, confidence interval; ERT, estrogen replacement therapy; HBCC, hospital-based case--control study; HRT, hormone replacement therapy; NA, data not available; PBCC, population-based case--control study; PRT, progesterone replacement therapy; *P~Q~*, *P*-value for *Q* statistic; RR, relative risk.
